Harnessing Cavitation for more than just delivery.
Sonodynamic therapy leverages the deep-tissue penetration of ultrasound to activate non-toxic sonosensitizing agents within a target site. This process generates localized reactive oxygen species (ROS) that induce selective cytotoxicity in malignant tissues. Our FUS transducers are engineered to provide the stable acoustic cavitation required to trigger these biochemical reactions, offering a potent, non-thermal approach to precision oncology.
Sonodynamic therapy has the efficacy of photodynamic therapy, without the depth limitations. FUS Instruments precision electronics enable the targeting of deep-seated tissue or tumors with repeated ultrasound exposures while sparing surrounding healthy tissue.
Weekly treatments of late-stage rat gliosarcoma tumors with sonosenitizer 5-ALA and FUS sonodynamic therapy (SDT) led to formation of a necrotic center, tumor shrinking and increased survival with 5-ALA/FUS/SDT.
This study used an early prototype model of the MRI-compatible RK-300.
Scientific Reports 15.1 (2025): 1161
Combination treatment of glioma in rat brains with sonosensitizer drug 5-ALA and FUS therapy (MRI-guided RK-300 prototype) shows significant reduction of proliferating Ki67+ tumor cells and increased apoptosis in the targeted tumor region.
Scientific reports 9.1 (2019): 10465
Three to five weeks of biweekly MRI-guided FUS/microbubble treatment shows decreased number and surface area of amyloid plaques in TgCRND8 mice.
Magnetic resonance-guided FUS (MRgFUS) treatments were performed using the RK-100 system (older version of RK-300).
Scientific reports 8.1 (2018): 14061
